var data={"title":"Ivabradine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ivabradine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243687?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ivabradine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ivabradine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27975706\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Corlanor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50192661\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lancora</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27787826\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Cardiovascular Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857551\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b>  Oral: Initial: 5 mg twice daily <b>or</b> 2.5 mg twice daily in patients with a history of conduction defects or who may experience hemodynamic compromise due to bradycardia. After 2 weeks, adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm). Thereafter, adjust dose as needed based on resting heart rate and tolerability. Maximum dose: 7.5 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dosage adjustment based on resting heart rate:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If heart rate &gt;60 bpm: Increase dose by 2.5 mg twice daily (maximum dose: 7.5 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If heart rate 50 to 60 bpm: Maintain dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If heart rate &lt;50 bpm or signs and symptoms of bradycardia: Decrease dose by 2.5 mg twice daily; if current dose is 2.5 mg twice daily, discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Inappropriate sinus tachycardia (off-label use):</b> Oral: Initial: 5 mg twice daily; maintenance: 7.5 mg twice daily (ACC/AHA/HRS [Page 2015]; Cappato 2012). May also use in combination with a beta-blocker (eg, metoprolol) in patients who are refractory to monotherapy (Ptaszynski 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Stable angina (off-label use):</b> Adults &lt;75 years: Oral: Initial: 2.5 to 5 mg twice daily; titrate up in increments of 2.5 mg after 3 to 4 weeks if symptoms persist and heart rate is greater than 60 bpm to a maximum dose of 7.5 mg twice daily. Discontinue therapy if angina symptoms do not improve within 3 months of initiation. Also consider discontinuation if improvement of angina symptoms is limited and no clinically significant heart rate reduction occurs in the first 3 months. If heart rate is lower than 50 bpm at rest or patient experiences symptomatic bradycardia (eg, dizziness, fatigue, hypotension) during therapy, decrease dose by 2.5 mg per dose, or discontinue if already at the minimum dose of 2.5 mg twice daily. Monitor heart rate carefully after dosage reduction. If heart rate continues to be lower than 50 bpm or symptoms of bradycardia persist, discontinue ivabradine (Corlentor 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If symptoms are not controlled on beta-blocker or calcium channel blocker monotherapy, addition of ivabradine can be considered. If combined with a calcium channel blocker, use of a dihydropyridine (such as slow-release nifedipine, amlodipine, or felodipine) is suggested (Montalescot 2013; NICE 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28616779\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stable angina (off-label use):</b> Adults &ge;75 years: Initial: Oral: Consider 2.5 mg twice daily. Titration and maintenance: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857552\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;15 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857553\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied; increase in systemic exposure anticipated).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27975707\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Corlanor: 5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Corlanor: 7.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27975705\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27788000\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Corlanor: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206143Orig1s002lbl.pdf </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857556\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27787828\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Heart failure:</b> To reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic (NYHA class II to III according to the ACC/AHA/HFSA heart failure guidelines [Yancy 2016]) chronic heart failure with left ventricular ejection fraction &le;35%, who are in sinus rhythm with resting heart rate &ge;70 beats per minute (bpm) and either are on maximally tolerated doses of beta blockers or have a contraindication to beta-blocker use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28616778\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Inappropriate sinus tachycardia; Stable angina</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28562238\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (6% to 10%), hypertension (9%), atrial fibrillation (5% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Phosphene (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Cardiovascular: Heart block, sinoatrial arrest</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, diplopia, erythema, hypotension, pruritus, skin rash, syncope, torsades de pointes, urticaria, ventricular fibrillation, ventricular tachycardia, vertigo, visual impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27787811\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute decompensated heart failure; blood pressure &lt;90/50 mm Hg; sick sinus syndrome, sinoatrial block, or third-degree AV block (unless a functioning demand pacemaker is present); resting heart rate &lt;60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence (heart rate maintained exclusively by the pacemaker); concomitant use with strong CYP3A4 inhibitors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to ivabradine or any component of the formulation; resting heart rate &lt;70 bpm prior to treatment; prolonged QT interval (eg, congenital long QT syndrome); cardiogenic shock; acute myocardial infarction; concomitant use of verapamil or diltiazem; pregnancy, breastfeeding, or women of child-bearing potential not using appropriate contraception; hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857538\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial fibrillation: Use increases the risk of atrial fibrillation; monitor cardiac rhythm. Discontinue if atrial fibrillation develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia and conduction disturbances: Bradycardia, sinus arrest, and heart block may occur; monitor heart rate prior to initiation and with any dosage adjustment. Bradycardia may increase the risk of QT prolongation, which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs. Risk factors for bradycardia include sinus node dysfunction, conduction defects (eg, first- or second-degree AV block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (eg, digoxin, diltiazem, verapamil, amiodarone). Avoid concurrent use with verapamil and diltiazem. Avoid use in patients with second-degree AV block (unless a functioning demand pacemaker is present). Use is contraindicated in patients with sick sinus syndrome, sinoatrial block, third-degree AV block (unless a functioning demand pacemaker is present), or pacemaker dependence. Decrease dose or discontinue use if heart rate &lt;50 bpm persists during therapy or signs and symptoms of bradycardia occur. Use is contraindicated in patients with pretreatment heart rate &lt;60 bpm. In patients with history of conduction defects or in whom bradycardia could lead to hemodynamic compromise, initial dosage reduction is recommended. Heart rate reduction may prolong the uncorrected QT interval while QTc interval remains unchanged (Camm 2003; Murat 2009). At concentrations slightly higher than that achieved with therapeutic dosing, ivabradine prolonged ventricular repolarization in perfused guinea-pig hearts (Melgari 2015). Torsades de pointes has been reported when used with other drugs that produce bradycardia or prolong the QT interval (Cocco 2015; Mittal 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual function: Phosphenes (described as transient enhanced brightness in a limited area of the visual field, halos, image decomposition, colored bright lights, or multiple images) may occur with use. Onset is generally within the first 2 months of therapy and is reported to be of mild to moderate intensity; most cases resolve during or after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28019062\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28019059\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101166&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the bradycardic effect of Ivabradine. Ivabradine may enhance the QTc-prolonging effect of Calcium Channel Blockers (Nondihydropyridine). Specifically, the QTc prolonging effects of bepridil may be enhanced. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ivabradine. Specifically, verapamil or diltiazem may increase serum ivabradine concentrations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the arrhythmogenic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the arrhythmogenic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857555\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Absorption delayed by 1 hour and AUC increased by 20% to 40% when taken with food. Management: Take with food to reduce variability in exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit juice: Exposure increased twofold after ingestion of grapefruit juice. Management: Avoid consumption of grapefruit juice (Nawarskas 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857535\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies, and fetal harm may occur if ivabradine is administered to pregnant women. Effective contraception is recommended in women of reproductive potential. If treatment is needed during pregnancy, closely monitor for destabilization of heart failure that could potentially result from heart rate slowing caused by ivabradine, especially during the first trimester. Pregnant women with chronic heart failure should also be monitored for preterm birth.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857537\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ivabradine is excreted in breast milk. Due to the potential risk from exposure in the nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857558\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate (prior to initiation, prior to increasing dose, or after decreasing dose); monitor heart rate more closely if receiving other negative chronotropes (eg, amiodarone, beta-blockers, digoxin); blood pressure; regularly monitor cardiac rhythm (assessing for atrial fibrillation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857541\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective and specific inhibition of the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels (f-channels) within the sinoatrial (SA) node of cardiac tissue resulting in disruption of If  ion current flow prolonging diastolic depolarization, slowing firing in the SA node, and ultimately reducing heart rate. Has not demonstrated effects on myocardial contractility or relaxation, ventricular repolarization, or conduction apart from the sinus node effects. Partial inhibition of the retinal <i>I</i><sub>h</sub> current (similar to the cardiac <i>I</i><sub>f</sub> current) may explain visual disturbances (eg, phosphenes) (Nawarskas 2015). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27857542\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~100 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively intestinal and hepatic via CYP3A4; major active metabolite equipotent to ivabradine is the N-desmethylated derivative (S 18982) which is also metabolized by CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~40%; AUC increased 20% to 40% with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Distribution: 2 hours; Effective: ~6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: ~1 hour (fasting); ~2 hours (with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~4% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326124\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Corlanor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $515.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (60): $515.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28018875\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Corabid (BD);</li>\n      <li>Coralan (AU, HK, ID, IL, IN, MY, PH, SG, TH, VN);</li>\n      <li>Coraxan (RU);</li>\n      <li>Corlentor (EE, ES, HR, MT, NL, RO);</li>\n      <li>Ivab (UA);</li>\n      <li>Ivacard (BD);</li>\n      <li>Ivanor (BD, LK);</li>\n      <li>Koraksan (UA);</li>\n      <li>Procoralan (AE, AR, AT, BE, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HN, HR, HU, IS, IT, JO, KR, KW, LB, LT, LU, LV, MT, MX, NI, NL, NO, PA, PL, PT, QA, RO, SA, SE, SI, SK, SV, TR);</li>\n      <li>Siftus (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Borer JS, B&ouml;hm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>Eur Heart J</i>. 2012;33(22):2813-2820.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/22927555/pubmed\" target=\"_blank\" id=\"22927555\">22927555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. <i>Drugs R D</i>. 2003;4(2):83-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/12718562/pubmed\" target=\"_blank\" id=\"12718562\">12718562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22981555\"></a>Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. <i>J Am Coll Cardiol</i>. 2012;60(15):1323-1329. doi: 10.1016/j.jacc.2012.06.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/22981555/pubmed\" target=\"_blank\" id=\"22981555\">22981555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cice G, D'Lsaa S, D'Andrea A, Russo MG, Zuccaro SM, Calabro R. Elderly patients with heart failure and preserved ejection fraction: effects of ivabradine [abstract]. Eur Heart J. 2013;34(suppl 1). http://eurheartj.oxfordjournals.org/content/34/suppl_1/P3329</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. <i>Cardiovasc Toxicol</i>. 2015;15(1):104-106. doi: 10.1007/s12012-014-9274-y.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/25158669/pubmed\" target=\"_blank\" id=\"25158669\">25158669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corlanor (ivabradine) [prescribing information]. Thousand Oaks, CA: Amgen Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corlentor (ivabradine) [EPAR product information]. Wicklow, Ireland: Servier Industries, Ltd; April 14, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>J Am Coll Cardiol</i>. 2012;60(24):e44-e164. doi: 10.1016/j.jacc.2012.07.013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/23182125/pubmed\" target=\"_blank\" id=\"23182125\">23182125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18757088\"></a>Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2008;372(9641):807-816.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/18757088/pubmed\" target=\"_blank\" id=\"18757088\">18757088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25176136\"></a>Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. <i>N Engl J Med</i>. 2014;371(12):1091-1099. doi: 10.1056/NEJMoa1406430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/25176136/pubmed\" target=\"_blank\" id=\"25176136\">25176136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lancora (ivabradine) [product monograph]. Laval, Quebec, Canada: Servier Canada Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Melgari D, Brack KE, Zhang C, et al. hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine. <i>J Am Heart Assoc</i>. 2015;4(4). pii: e001813. doi: 10.1161/JAHA.115.001813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/25911606/pubmed\" target=\"_blank\" id=\"25911606\">25911606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine. <i>J Assoc Physicians India</i>. 2014;62(5):426-427.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/25438492/pubmed\" target=\"_blank\" id=\"25438492\">25438492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23996286\"></a>Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>Eur Heart J</i>. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/23996286/pubmed\" target=\"_blank\" id=\"23996286\">23996286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murat SN, Orcan S, Akdemir R, Dogan M, Kara E, Balci M. Arrhythmic effects of ivabradine in patients with coronary artery disease. <i>Clin Invest Med</i>. 2009;32(5):E322-E326.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/19796572/pubmed\" target=\"_blank\" id=\"19796572\">19796572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Care Excellence. Management of stable angina (NICE clinical guideline 126). http://guidance.nice.org.uk/cg126. Published July 2011. Updated December 2012. Accessed June 3, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nawarskas JJ, Bowman BN, Anderson JR. Ivabradine: A unique and intriguing medication for treating cardiovascular disease. <i>Cardiol Rev</i>. 2015; epub ahead of print.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/25839989/pubmed\" target=\"_blank\" id=\"25839989\">25839989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2015. pii: S0735-1097(15)05840-4. doi: 10.1016/j.jacc.2015.08.856.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23426376\"></a>Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. <i>J Cardiovasc Pharmacol Ther</i>. 2013;18(4):338-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/23426376/pubmed\" target=\"_blank\" id=\"23426376\">23426376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20801500\"></a>Swedberg K, Komajda M, B&ouml;hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet</i>. 2010;376(9744):875-885.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/20801500/pubmed\" target=\"_blank\" id=\"20801500\">20801500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19136486\"></a>Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>Eur Heart J</i>. 2009;30(5):540-548. doi: 10.1093/eurheartj/ehn571.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/19136486/pubmed\" target=\"_blank\" id=\"19136486\">19136486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published online May 20, 2016]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivabradine-drug-information/abstract-text/27208050/pubmed\" target=\"_blank\" id=\"27208050\">27208050</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101166 Version 51.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27975706\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50192661\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F27787826\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F27857551\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28616779\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F27857552\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F27857553\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F27975707\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F27975705\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F27788000\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27857556\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F27787828\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28616778\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28562238\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F27787811\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F27857538\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28019062\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28019059\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F27857555\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F27857535\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F27857537\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27857558\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F27857541\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F27857542\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28326124\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F28018875\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/101166|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ivabradine-patient-drug-information\" class=\"drug drug_patient\">Ivabradine: Patient drug information</a></li></ul></div></div>","javascript":null}